Citius Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) covers the 2020 Annual Meeting of Stockholders held on February 10, 2020. Citius Pharmaceuticals, Inc. is a Nevada corporation with its principal executive offices in Cranford, NJ. The company's common stock (CTXR) and warrants (CTXRW) trade on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and voting results rather than financial performance.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Board of Directors Election: Stockholders elected seven directors for a term expiring in 2021. All nominees received unanimous support with zero votes against.
- Myron Holubiak: 14,443,668 For
- Leonard Mazur: 14,443,873 For
- Suren Dutia: 14,443,918 For
- Carol Webb: 14,444,066 For
- Dr. William Kane: 14,444,309 For
- Howard Safir: 14,443,714 For
- Dr. Eugene Holuka: 14,444,159 For
- Ratification of Auditors: Stockholders ratified the selection of Wolf & Company, P.C. as the independent registered public accounting firm for the fiscal year ending September 30, 2020.
- For: 21,534,941 shares
- Against: 65,367 shares
- Abstaining: 126,612 shares
- Stock Incentive Plan Approval: Stockholders approved the 2020 Omnibus Stock Incentive Plan.
- For: 14,218,736 shares
- Against: 200,225 shares
- Abstaining: 49,623 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to reporting the outcomes of the shareholder vote.
Investor Verification Checklist
- Verify the total number of shares outstanding and the percentage of shares represented at the meeting to assess the significance of the voting results.
- Confirm the specific terms and share limits of the newly approved 2020 Omnibus Stock Incentive Plan in the definitive plan document.
- Review the company's most recent 10-K or 10-Q for financial metrics, as this 8-K contains no financial data.
- Check for any subsequent filings regarding the implementation of the new stock incentive plan.